Enterome - Model EO2463 -Innovative, Off-The-Shelf Therapeutic Cancer Vaccine
EO2463 is an innovative, off-the-shelf therapeutic cancer vaccine discovered by Enterome. EO2463 combines four OncoMimics peptides (bacterial peptides) of B lymphocyte-specific lineage markers. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in indolent non-Hodgkin lymphoma (iNHL). EO2463 is being evaluated in a Phase 1/2 clinical trial as monotherapy and in combination with standard-of-care lenalidomide and/or rituximab for the treatment of iNHL (SIDNEY study, EONHL1-20).
SIDNEY (EONHL1-20) is a multicenter, open-label, first-in-human, Phase 1/2 study of EO2463 as monotherapy and in combination with lenalidomide and/or rituximab for the treatment of patients with indolent non-Hodgkin lymphoma (iNHL).
The study aims to assess safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in approximately 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL).
The study has received regulatory approvals in Italy, Spain, France and the USA with the clearance of the Investigational New Drug (IND). The first patient is expected to be dosed in Q2 2021.
ClinicalTrials.gov Identifier: NCT04669171